共 261 条
[1]
Hasset MJ(2006)Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer J Natl Cancer Inst 98 1108-1117
[2]
O’Malley AJ(2007)Risk-adapted strategy for the management of febrile neutropenia in cancer patients Support Care Cancer 15 477-482
[3]
Pakes JR(2006)Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment Support Care Cancer 14 901-909
[4]
Newhouse JP(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266
[5]
Earle CC(2011)European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte colony-stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 8-32
[6]
Klastersky J(2013)Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology clinical practice guideline J Clin Oncol 31 794-810
[7]
Paesmans M(2006)2006 Update of recommendations for the Use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205
[8]
Schwenkglenks M(2010)Hematopoietic growth factors: ESMO clinical practice guidelines for the applications Ann Oncol 21 v248-v251
[9]
Jackisch C(2011)Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study Support Care Cancer 19 483-490
[10]
Constenla M(2009)Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer Ann Oncol 20 34-40